artrose osteoarthritis
Conditions
Interventions
One group receives no treatment for 4 weeks, the second group receives 2x daily
200mg celecoxib for 4 weeks until surgery, the third group receives 2x daily
200mg celecoxib for 4 weeks until 3 days
Sponsors
Sint Franciscus Gasthuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with knee osteoarthritis, who are eligible for and on the waiting list for total knee replacement surgery. Patients will be treated at the Sint Franciscus Gasthuis Hospital in Rotterdam.
Exclusion criteria
Exclusion criteria: Patients who are eligible for a total knee replacement operation for other reasons than osteoarthritis. Patients with an increased risk of gastro-intestinal bleeding. Patients with an increased risk of cardio-vascular disease such as a history of cardio-vascular disease like myocardium infarct, heart failure, CVA and TIA; patients with untreated/insufficiently treated hypertension; patients with angina pectoris and patients on oral anticoagulants. Patients with serious liver and/or kidney function impairment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome parameter is the difference in proteoglycan release of the OA cartilage under the influence of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome parameters are changes in several biochemical and histochemical characteristics of the OA cartilage including proteoglycan synthesis rate, proteoglycan content, prostaglandin E2 (PGE2) production, and COX-1 and COX-2 expression of cartilage. The tertiary outcome measures are changes in synovial tissue due to treatment measured by biochemical and histochemical techniques, including IL-1 and TNFa production, COX expression, and protease activity. | — |
Countries
Netherlands
Outcome results
None listed